Encision Reports Profitable First Fiscal Quarter Results

BOULDER, Colo., July 30 /PRNewswire-FirstCall/ -- Encision Inc. (OTC Bulletin
Board: ECIA), a medical device company owning patented surgical technology
that is emerging as a standard of care in minimally-invasive surgery, reported
its financial results for its first quarter of fiscal year 2010.

Net sales for the three-months ended June 30, 2009 totaled $3.2 million,
representing a 3% increase over net sales of $3.1 million for the prior fiscal
year's first quarter. The Company recorded net income of $163 thousand or $.03
per share for the first quarter of fiscal year 2010, compared to a net loss of
$164 thousand or ($.03) per share for the first quarter of fiscal year 2009.
Gross profit margin for the first quarter of fiscal year 2010 was 64%, as
compared to 60.3% for the first quarter of fiscal year 2009, a 3.7% increase
resulting from production efficiencies and an increase to inventory which
resulted in a higher absorption of overhead costs to inventory and a decrease
to cost of sales.

"We are pleased with the start to our first quarter of fiscal year 2010,
especially with the turnaround from last year's first quarter net loss. Net
income increased from last year's first quarter net loss as a result of a
slight increase in sales income, increased gross profit margin and reduced
operating expenses," said Jack Serino, President and CEO of Encision Inc.

Encision Inc. designs, develops, manufactures and markets innovative surgical
devices that allow surgeons to optimize technique and patient safety during a
broad range of surgical procedures. Based in Boulder, Colorado, the Company
pioneered the development of patented AEM(R) Laparoscopic Instruments to
improve electrosurgery and reduce the chance for patient injury in minimally
invasive surgery.

In accordance with the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, the Company notes that statements in this press
release and elsewhere that look forward in time, which include everything
other than historical information, involve risks and uncertainties that may
cause actual results to differ materially from those indicated by the
forward-looking statements. Factors that could cause the Company's actual
results to differ materially include, among others, its ability to increase
net sales through the Company's distribution channels, insufficient quantity
of new account conversions, insufficient cash to fund operations, scale up
production to meet delivery obligations, delay in developing new products and
receiving FDA approval for such new products and other factors discussed in
the Company's filings with the Securities and Exchange Commission. Readers are
encouraged to review the risk factors and other disclosures appearing in our
filings with the Securities and Exchange Commission. We do not undertake any
obligation to update publicly any forward-looking statements, whether as a
result of the receipt of new information, future events, or otherwise.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600,
mmchaffie@encision.com

Encision Inc.
Condensed Balance Sheets
(Amounts in thousands)

June 30, March 31,
2009 2009
(Unaudited) (Audited)
----------- ---------
ASSETS
Cash and cash equivalents $126 $85
Accounts receivable, net 1,235 1,264
Inventories, net 2,459 2,505
Prepaid expenses 110 36
--- --
Total current assets 3,930 3,890
----- -----
Equipment, net 884 840
Patents, net 223 216
Other assets 18 24
-- --
Total assets $5,055 $4,970
------ ------
LIABILITIES AND SHAREHOLDERS'
EQUITY
Accounts payable $662 $745
Accrued compensation 311 406
Other accrued liabilities 360 367
Line of credit 275 191
--- ---
Total current liabilities 1,608 1,709
----- -----
Common stock and additional
paid-in capital 19,582 19,560
Accumulated (deficit) (16,135) (16,299)
------- -------
Total shareholders' equity 3,447 3,261
----- -----
Total liabilities and
shareholders' equity $5,055 $4,970
------ ------

Encision Inc.
Condensed Statements of Operations
(Amounts in thousands, except per share information)

(Unaudited)
Three Months Ended
------------------
June 30, June 30,
2009 2008
-------- --------
Net sales $3,174 $3,094
Cost of sales 1,142 1,229
----- -----
Gross profit 2,032 1,865
----- -----
Operating expenses:
Sales and marketing 1,199 1,374
General and administrative 354 367
Research and development 301 289
--- ---
Total operating expenses 1,854 2,030
----- -----
Operating income (loss) 178 (165)
Interest and other income
(expense), net (15) 1
--- ---
Income (loss) before provision
for income taxes 163 (164)
Provision for income taxes - -
--- ---
Net income (loss) $163 $(164)
==== =====
Net income (loss) per
share-basic and diluted $0.03 $(0.03)
Basic and diluted weighted
average number of shares 6,455 6,450

SOURCE Encision Inc.

Marcia McHaffie of Encision Inc., +1-303-444-2600, mmchaffie@encision.com